Discover.
Launch.
Build.
Transform.

Living our core values.

One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. We support our communities of color in Boston and San Francisco - and everywhere in between.

MOMA Therapeutics

The current era of disease genetics and whole genome profiling have defined molecular machines as the best intervention points in numerous diseases. MOMA's mission is to discover the next generation of precision medicines by targeting the molecular machines that underlie diseases.

MOMA Therapeutics

Blueprint Medicines

Blueprint received approval from the U.S. Food and Drug Administration (FDA) for GAVRETO™ (pralsetinib) for the treatment of adult patients with RET fusion-positive non-small cell lung cancer. This approval brings forward a new standard of care for a genomically defined population of patients that previously had very limited treatment options.

Blueprint Medicines

GBT

GBT received accelerated approval from the U.S. Food and Drug Administration (FDA) for Oxbryta™ (voxelotor) for the treatment of sickle cell disease (SCD). The once-daily pill is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.

GBT

Thrive Earlier Detection

Cancer is often detected too late, when it has become challenging to treat and may have spread from one area in the body to others. Thrive is developing a high performance, highly targeted, blood-based screening approach, called CancerSEEK, designed to be implemented into routine medical care with the goal of identifying cancer at earlier stages across multiple cancer types.

THRIVE EARLIER DETECTION

Agios Pharmaceuticals

Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases. With remarkable speed - about 10 years - Agios brought two therapeutics to the market. And now patients with acute myeloid leukemia have treatment options they didn’t have before.

AGIOS PHARMACEUTICALS
13

Years

54

Portfolio Companies

13

Marketed Products

1

Priority: Patients